Morphinan compounds

• US 9,314,440 B2
• Filed: 07/17/2014
• Issued: 04/19/2016
• Est. Priority Date: 05/01/2007
• Status: Active Grant

• Current Assignee: Concert Pharmaceuticals Inc. (Sun Pharmaceutical Industries Limited)
• Original Assignee: Concert Pharmaceuticals Inc. (Sun Pharmaceutical Industries Limited)
• Inventors: Tung, Roger
• Primary Examiner(s): Aulakh, Charanjit
• Application Number:
  US14/334,227
• Publication Number:
  US 20140329846A1
• Time in Patent Office: 642 Days
• Field of Search: 514/289
• US Class Current: 1/1
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 31/49 Cinchonan derivatives, e.g. quinine
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/14 Antitussive agents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C07B 59/002 Heterocyclic compounds
• CPC Class Codes: C07D 221/28 Morphinans
• CPC Class Codes: C07D 471/08 Bridged systems
• CPC Class Codes: C12Q 1/28 involving peroxidase
• CPC Class Codes: G01N 33/491 by separating the blood components G01N15/05 takes precedence
• CPC Class Codes: G01N 33/493 urine

Abstract

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ₁ receptor agonist that also has NMDA antagonist activity.

Claims

1. A method for treating a subject suffering from or susceptible to Parkinson'"'"'s Disease, the method comprising administering to the subject a compound of formula (I):

2. The method of claim 1, wherein R¹ is CD₃, and R² is selected from CH₃, CH₂D, CHD₂, and CD₃.

3. The method of claim 2, wherein R¹ is CD₃, and R² is CD₃.

4. The method of claim 2, wherein R¹ is CD₃, and R² is CH₃.

5. The method of claim 1, wherein the compound of formula (I):

6. The method of claim 1, wherein the pharmaceutically acceptable salt is the HBr salt.

7. The method of claim 1, further comprising administering to the subject in need thereof a second therapeutic agent selected from quinidine or a salt thereof, oxycodone, and gabapentin.

8. The method of claim 7, wherein R¹ is CD₃, and R² is selected from CH₃, CH₂D, CHD₂, and CD₃.

9. The method of claim 8, wherein R¹ is CD₃, and R² is CD₃.

10. The method of claim 8, wherein R¹ is CD₃, and R² is CH₃.

11. The method of claim 7, wherein the second therapeutic agent is quinidine or quinidine sulfate.